<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02187757</url>
  </required_header>
  <id_info>
    <org_study_id>Prelip/Nutra001/PMI13</org_study_id>
    <nct_id>NCT02187757</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels</brief_title>
  <acronym>Prelip</acronym>
  <official_title>A Prospective, Double Blind, Placebo-Controlled, Randomized, Multicentric, Study to Evaluate the Safety, Efficacy and Tolerability of PreLipid®, a Twice-daily Nutritional Supplement in Subjects With Higher Than Normal Blood Lipid Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PreEmptive Meds, Pvt. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PreEmptive Meds, Pvt. Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate Efficacy and Safety of PreLipid® on subjects with higher than normal blood
      lipid levels
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Prospective, Double Blind, Placebo-Controlled, Randomized, Multicentric, study to evaluate
      the safety, efficacy and tolerability of PreLipid®, a twice-daily nutritional supplement in
      subjects with higher than normal blood lipid levels
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Dietary Supplement PreLipid 600 mg twice-daily in lowering LDL-C levels</measure>
    <time_frame>Day 1 (Baseline) to Day 90 (End of Study)</time_frame>
    <description>Change in LDL-C % from baseline (Day 1) to the end of supplementation/treatment after 90 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of Dietary Supplement PreLipid 600 mg twice-daily</measure>
    <time_frame>Day 1(Baseline) to Day 90 (End of Study)</time_frame>
    <description>Measure changes in Liver Function Tests: Aspartate Aminotransferase (AST) from baseline (Day 1) to End of Study (Day 90); Alanine Aminotransferase (ALT) from baseline (Day 1) to End of Study (Day 90) and Alkaline Phosphatase (ALP) from baseline (Day 1) to End of Study (Day 90)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Glycemic Status</measure>
    <time_frame>Day 1 (Baseline) to Day 90 (End of Study)</time_frame>
    <description>To assess percentage changes in Blood Sugar profile (HbA1c) from baseline to at the end of supplementation after 03 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of Dietary Supplement PreLipid 600 mg twice-daily with Kidney Function</measure>
    <time_frame>Baseline (Day 1) to End of Study (Day 90)</time_frame>
    <description>Measure changes in Renal Function Tests: Blood Urea Nitrogen (BUN) from baseline (Day 1) to End of Study (Day 90); Serum Creatinine from baseline (Day 1) to End of Study (Day 90)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>PreLipid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90days along with lifestyle modification.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 600 mg capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo was given to patients twice daily 30 mins before food for 90 days along with lifestyle modification program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Study Dietary Supplement (Prelipid 500 mg capsules)</intervention_name>
    <description>Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with lifestyle modification.</description>
    <arm_group_label>PreLipid</arm_group_label>
    <other_name>PreLipid, Natural Cholesterol Supplement, Predisease</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo 600 mg capsules</arm_group_label>
    <other_name>Placebo 600 mg capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Newly diagnosed Male or Female participants with higher than normal cholesterol levels
        defined by the American Heart Association, National Cholesterol Education Program (NCEP)
        and ATP-III goals for LDL cholesterol and cut off points for therapeutic lifestyle changes
        (TLCs) and drug therapy in different risk categories:

          1. Age ≥ 18 years to ≤ 65 years

          2. LDL cholesterol levels &gt;120mg/dl

          3. Ability to understand and willingness to sign and date a written Informed Consent
             Document at the screening visit before any protocol- specific procedures are performed
             and willing to adhere to the protocol and entire trial procedures -

        Exclusion Criteria:

          1. Stroke, myocardial infarction, coronary artery bypass graft (CABG) percutaneous
             transluminal coronary angioplasty (PTCA) or angina pectoris in the past.

          2. Cardiac status New York Heart Association class III-IV

          3. Uncotrolled blood pressure &gt; 150 mmhg systolic and &gt; 100 mmhg diastolic

          4. Impaired renal function as shown by but not limited to serum creatinine ≥ 1.5 mg/dl
             for males and ≥ 1.4 mg/dl for female

          5. Clinically significant peripheral edema

          6. Clinical evidence of active liver disease or serum alenine aminotransferase (ALT) or
             aspartate amino transferase (AST) 2.5 times the upper limit of the normal range (2.5 X
             ULN)

          7. Participants on steroid

          8. Pregnancy or lactating women

          9. Known hypersensitivity to any of the study drugs

         10. Any malignancy within the last 5 years, with exception of adequately treated basal or
             squamous cell carcinoma of the skin or adequately treated carcinoma insitu.

         11. Current addiction or current alcohol abuse or history of substance or alcohol abuse
             within the last 2 years

         12. Subject is the investigator or any sub-investigator, research assistant, pharmacist,
             study coordinator, other staff or relative thereof directly involved in the conduct of
             the protocol

         13. Mental condition rendering the subject unable to understand the nature, scope and
             possible consequences of the study.

         14. Subject unlikely to comply with protocol e.g. uncooperative attitude, inability to
             return for follow up visits and unlikelihood completing of the study

         15. Any disease or condition that in the opinion of the investigator and/or sponsor may
             interfere with the completion of the studyevaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravi Kasliwal, MD, DM, FIMSA</last_name>
    <role>Study Chair</role>
    <affiliation>Medanta, The Medicity, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Clinical &amp; Preventive Cardiology, Heart Institute</name>
      <address>
        <city>Gurgaon</city>
        <state>Delhi</state>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Life Care Institute of Medical Science &amp; Research</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhatia Hospital Medical Research Society</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Vikas Govind Pai Clinical Research Foundation</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fortis Escorts Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pace Clinical Research Center</name>
      <address>
        <city>Bangalore</city>
        <state>Tamil Nadu</state>
        <zip>560043</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singvi Health Centre</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600079</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rangammal Hospital</name>
      <address>
        <city>Tiruvannamalai</city>
        <state>Tamil Nadu</state>
        <zip>606003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2014</study_first_posted>
  <last_update_submitted>May 14, 2015</last_update_submitted>
  <last_update_submitted_qc>May 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medanta, The Medicity, India</investigator_affiliation>
    <investigator_full_name>Joe Fenn</investigator_full_name>
    <investigator_title>Chairman, Department of Clinical &amp; Preventive Cardiology</investigator_title>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>High cholesterol</keyword>
  <keyword>High LDL</keyword>
  <keyword>Triglycerides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

